Dr. Braithwaite has a broad background in the field of neuroscience with a particular focus on cognitive processes and neurodegenerative disorders. He received his degree in natural sciences from University of Cambridge, UK, completed his PhD at University of Bristol, UK followed by postdoctoral work at Stanford University. For more than 10 years he has led research and directed drug discovery and development programs at both large pharmaceutical and small biotechnology companies in the field of neuroscience. At AGY Therapeutics Dr. Braithwaite led a phosphatase targeted program for schizophrenia and cognitive disorders. At Wyeth Research he headed the Cellular Neurodegeneration and Regeneration group, leading programs for both Alzheimer’s and Parkinson’s diseases. Currently, as the senior vice president of Drug Discovery at Signum Biosciences, he leads a program to modulate PP2A for neurodegenerative disorders. Publication in the field attests to his study of basic mechanisms in order to drive therapeutic development.